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Abstract p300 and CBP are two related transcriptional co-
activator proteins required by many cellular transcription factors 
for activity. The adenovirus El A protein binds p300 and CBP 
through its amino-terminus and conserved region (CR) 1. Fusing 
CR1 to a heterologous DNA-binding domain creates a potent 
transcriptional activator, suggesting that CR1 might activate 
transcription by recruiting p300/CBP to the promoter. We show 
that both p300 and CBP enhances CRl-dependent transactiva-
tion. However, this enhancement occurs independently of a direct 
interaction with E1A and does not correlate with the CR1 
activator function. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The adenovirus El A proteins transactivate the adenovirus 
early promoters, induce S-phase in the host cell and immortal-
ize rodent cells. These activities are mediated by cellular pro-
teins associating with the El A proteins. Three conserved re-
gions (CR1, 2 and 3) and the extreme N-terminus of the 
protein are involved in binding multiple cellular proteins (re-
viewed in [1]). Activation of transcription in HeLa cells is 
mainly mediated by the E1A CR3 domain which interacts 
with a number of transcription factors, allowing El A, which 
by itself does not bind DNA, to associate with the promoter 
region [2]. In contrast, in primary cells, efficient transactiva-
tion of the adenovirus early promoters require both the CR1 
and the CR3 domains [3,4]. This result suggests that factors 
associating to the CR1 domain play an important role in El A 
transactivation during the natural virus life cycle. Interest-
ingly, the CR1 domain has an intrinsic transactivation ca-
pacity. Thus, fusing CR1 to a heterologous DNA-binding 
domain creates a transcriptional activator which is as potent 
as the CR3 domain [5-7]. 
The CR1 domain has been shown to be of critical impor-
tance for a lytic adenovirus infection by forcing infected cells 
to enter the S-phase. This appears to be accomplished in two 
ways. First, the CR1 and CR2 domains of E1A bind the 
Retinoblastoma protein and its relatives pi07 and pi30. 
This results in a release of the E2F family of transcription 
factors, which are needed to activate genes required for 
DNA synthesis, from inhibitory complexes with the Retino-
blastoma family of proteins (reviewed in [8]). In the second 
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pathway, E1A prevents host cell differentiation by repressing 
transcription of differentiation specific genes. This is accom-
plished by binding of the highly related transcriptional co-
activator proteins p300 [9] and CREB-binding protein 
(CBP) [10] to the El A N-terminus and the CR1 domain 
[11-14]. 
Recent data show that many unrelated transcription factors 
require the p300/CBP co-activator proteins for activity (re-
viewed in [15]). Interestingly, p300/CBP associate with the 
histone acetyltransferase p/CAF [16] and in addition posses 
intrinsic histone acetylase activity [17,18]. Collectively, avail-
able data suggest that p300/CBP may activate transcription by 
inducing chromatin remodelling. In our earlier work we 
showed that mutations eliminating El A binding of the Reti-
noblastoma family of proteins did not affect the CR1 trans-
activation function, whereas a mutation that would be pre-
dicted to affect p300/CBP binding resulted in crippling of the 
activator function. This finding raised the possibility that CR1 
functions as a transactivator by recruiting the p300/CBP co-
activator proteins to the promoter. Here we show that both 
p300 and CBP stimulate CRl-dependent transactivation. 
However, by using mutants of El A and p300 we also show 
that this stimulation is independent of an interaction with 
El A. Thus, we conclude that neither CBP nor p300 is the 
critical co-activator protein required for the El A CR1 trans-
activation function. 
2. Materials and methods 
2.1. DNA constructs 
Most Gal4 fusion plasmids have previously been described [5,19] as 
have the CAT reporter constructs [20]. All Gal4 fusion proteins en-
code the DNA-binding domain [amino acids (aa) 1-147] of Gal4 fused 
to different parts of E1A. The nomenclature used to name plasmids 
are as follows; Met, R, and C indicate that the junction between the 
Gal4 region and E1A sequence are at the E1A initiation codon (Met), 
the Rsal site at nucleotide 636 (R) or the Clal site at position 917 (C). 
Boff and Doff indicate that a translational stop codon was introduced 
after the BspEl (position 825) or Ddel (position 1241) restriction sites, 
respectively. Gal-MetBoffACRl was constructed by transfer of the 
ACR1 mutation from pML005ACRl [5] to Gal4-MetBofT. Gal-
Raa75 and Gal-Raa60 are PCR variants of Gal-RBoff that introduce 
stop codons after aa 75 and aa 60 of E1A, respectively. PCR clones 
were verified by sequencing. Gal-Raa68 was constructed by ligating 
the &oRI-blunt ended A vdl fragment of Gal-RBoff into £coRI-blunt 
ended Xba\ of Gal-R12SXoff. 
Plasmids expressing Glutathione S-transferase (GST) fusion pro-
teins were constructed by transfer of the E1A part of Gal4 fusion 
plasmids into either the pGEX-1 W or pGEX-2T vectors (Pharmacia). 
Plasmids pRc/CMV-mCBP-HA [10] (here designated plasmid CBP), 
CMVP-p300-CHA and CMV|3-p300del30 [9] (here designated plas-
mids p300 and p300del30) express CBP and p300 proteins with an 
HA epitope tag fused to the C-terminus. The CMV promoter back-
bone plasmid has been described (designated pSCT in [21]). 
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2.2. Transfection and reporter gene analysis 
Subconfluent HeLa monolayer cells were grown and transfected by 
the calcium phosphate coprecipitation technique as previously de-
scribed [5]. When necessary, transfections were supplemented with 
either pUC 19 or salmon sperm DNA up to a total of 12-15 ug of 
DNA per 60 mm dish. Three ug of CAT reporter plasmid was trans-
fected with 0.2 |ig of Gal-El A fusion plasmids and 1 or 5 ug of empty 
CMV vector, or p300 or CBP expressing plasmids. CAT extracts were 
prepared by freeze-thawing [5]. Different amounts of extract were 
assayed to allow accurate quantitation of strong activators. All experi-
ments were performed at least three times. Data were quantitated by 
phosphorimager analysis using a Molecular Dynamics or BioRad 
machine. 
2.3. GST-binding assay 
GST fusion proteins were expressed in E. coli and purified on glu-
tathione-Sepharose as described in the Pharmacia manual. Similar 
amounts of GST fusion proteins were incubated with 8 JJ.1 in vitro 
translated 35S labelled CBP or the C-terminus of p300 in 400 ul of 
NTN buffer (20 mM Tris pH 7.5, 100 mM NaCl and 0.5% NP40) for 
one hour at 4°C. The beads were washed three times with the same 
buffer, bound proteins eluted with loading buffer and resolved on 
7.5% SDS-PAGE gels. pRc/CMV-mCBP-HA was used for in vitro 
transcription/translation of CBP. An oligonucleotide containing a 
T7 RNA polymerase promoter, an ATG translation initiation codon 
and sequence complementary to p300 beginning at aa 1613 (5'-
ATTAATACGACTCACTATAGGCACCATGGTTGATCCTGAT-
CCTC-3') together with an oligo complementary to the HA epitope 
(5'-TATCTATCCGAGGGAGGCGTAGTC-3') was used to amplify 
the C-terminus of p300 by PCR. Coupled in vitro transcription/ 
translation was performed in a wheat germ extract (Promega). We 
were unable to generate full-length in vitro translated CBP, the prod-
uct migrates at approximately 180 kDa. The C-terminus of p300 mi-
grates with a somewhat larger size than expected (approximately 95 
kDa instead of 86 kDa). 
3. Results 
3.1. El A CR1 transactivation, but not CR3 activation, 
is stimulated by p300 and CBP expression 
We have shown that fusion of the first 90 amino acids (aa) 
of El A, including CR1, to the DNA-binding domain of the 
yeast transcription factor Gal4, results in an activator at least 
as potent as the previously described Gal-CR3 fusion protein 
[5]. We also showed that mutation of El A aa 66-68 dramat-
ically reduced transactivation. This mutation is expected to 
eliminate p300/CBP binding to El A [3] and we therefore 
tested the involvement of these proteins in transcription acti-
vation by the CR1 domain. HeLa cells were transfected with 
Gal-MetBoff (E1A aa 1-90) and the G1E1BCAT reporter 
containing a single Gal4 DNA-binding site, in the absence 
or presence of p300 or CBP. As shown in Fig. 1, co-trans-
fection of either p300 or CBP stimulated CR1 transactivation 
in a dose-dependent manner. The amount of CR1 activator in 
this and the following experiments was titrated to give only 
minimal activation, thereby allowing the visualization of the 
effects of p300 and CBP. Interestingly, Gal-CR3 activation 
(Gal-CDoff) was largely unaffected by p300 or CBP co-trans-
fection (Fig. 1). The small effect seen on Gal-CR3 activation 
was similar to the effect of p300/CBP on the reporter alone. 
However, p300 and CBP co-transfection stimulated transcrip-
tion by the unrelated activators Gal-VP16 (Fig. 1) and Gal-
c-jun (not shown). Thus, although p300 and CBP will stim-
ulate transcription of a number of activation domains, the 
effect on El A transactivation is specific to the CR1 activa-
tor. 
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Fig. 1. p300 and CBP stimulate Gal-El A CR1 transactivation in a 
dose-dependent manner. Gal-MetBoff (expressing aa 1-90 of E1A, 
including CR1), Gal-VP16 and Gal-CDoff (aa 121-192 of E1A, in-
cluding CR3) were transfected with the G1E1BCAT reporter plas-
mid in the absence or presence of increasing amounts of plasmids 
p300 or CBP. Shown is a schematic representation of the E1A-289R 
protein (top) as well as the Gal4 fusion proteins (left) and a repre-
sentative CAT assay to the right. 
3.2. Transactivation defective mutants of El A are stimulated 
by p300 expression 
In the context of the wild type (wt) El A protein the N-
terminus is critical for binding of p300/CBP [12]. However, 
removal of the first 27 aa creates a transactivation domain, 
Gal-RBoff (ElA aa 28-90), that is even more potent than 
Gal-MetBoff ([5]; see also Fig. 5A). This protein was stimu-
lated to a similar extent as Gal-MetBoff by p300 or CBP co-
transfection (see below). Interestingly, the substitution mutant 
Gal-RBoff sub66-68 which has lost almost all of its trans-
activation function was still stimulated by p300 co-transfec-
tion (Fig. 2). Thus, the transactivation capacity of the Gal-
E1A fusion proteins does not correlate with p300 stimulation. 
This conclusion is consistent with the effect of p300 expression 
on C-terminally truncated variants of Gal-RBoff (Fig. 2). 
These truncated proteins progressively lose their transactiva-
tion capacity as assayed on the G5E1BCAT reporter. How-
ever, as shown in Fig. 2, Gal-Raa75 (E1A aa 28-75) and Gal-
Raa68 (E1A aa 28-68) were stimulated by p300 expression to 
a similar extent as Gal-RBoff. In contrast, Gal-Raa60 (E1A 
aa 28-60) was not stimulated by p300 co-transfection. This is 
not because p300 stimulation requires a functional CR1 acti-
vation domain, since mutating aa 66-68 (Gal-RBoff sub66-
68) eliminated transactivation but still allowed for p300 stim-
ulation (Fig. 2). Similar results were obtained for CBP (not 
shown). Taken together, these results suggest that stimulation 
by p300 or CBP does not correlate with the CR1 transactiva-
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Fig. 2. Stimulation of transcription by p300 does not correlate with the transactivation capacity of CR1. Gal-RBoff (ElA aa 28-90) and mu-
tants thereof were co-transfected with the G5E1BCAT reporter plasmid in the absence or presence of p300 plasmid. A schematic representation 
of the E1A-243R protein (top) and the Gal4 fusion proteins (left), a representative CAT assay and a quantitation thereof is shown. Note that 
the quantitative result is given as fold stimulation caused by p300 co-transfection and not the relative activity of each mutant protein. 0 , Since 
Gal-RBoff is a very potent transactivator protein only 5 ul of extract was assayed, while 150 ul extract of the other mutants was assayed. 
tion function. The results further suggest that aa 60-66 are 
critical for p300 stimulation. 
The results presented this far indicate that residues critical 
for the interaction between E l A and p300/CBP in the E l A wt 
context are not required for p300/CBP stimulation of Gal-
E I A transcription. Thus, p300 and CBP enhancement of 
Ga l -E IA transcription appears to be independent of an inter-
action with E l A . To further test this hypothesis, we deter-
mined whether the p300 mutan t protein p300del30 which is 
unable to interact with E l A [9] stimulates Ga l -E IA transcrip-
tion. As shown in Fig. 3, p300del30 co-transfection stimulates 
Gal-MetBoff and its derivatives to a similar extent as wt p300. 
Taken together, these results suggest that p300 stimulates Gal-
E I A transcription-independent of a direct interaction with the 
E l A protein. 
The da ta shown in Fig. 2 indicate that C R 1 , in the absence 
of the N-terminus, is sufficient for p300 stimulation. To test 
whether CR1 is required for p300 stimulation, we compared 
the effect of p300 co-transfection on Gal-R12SE/P- ( E l A aa 
28-142) and Gal-R12SE/P-ACR1 (removing aa 38-65) trans-
activation. As shown in Fig. 4, deletion of both CR1 and the 
N-terminus (Gal-R12SE/P-ACR1) eliminated transactivation 
as well as p300 stimulation. Interestingly, the N-terminus 
(Gal-MetBoffACRl), although unable to activate transcrip-
tion by itself, was stimulated by p300 co-transfection (Fig. 
4). Collectively these results show that the E l A N-terminus 
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Fig. 3. A p300 mutant protein (p300del30) unable to bind to ElA stimulates Gal-EIA transcription. Gal-MetBoff and mutants thereof were 
tested for stimulation by p300 or p300del30 co-transfection. Shown is a schematic picture of the E1A-243R protein (top) and the Gal4 fusion 
proteins (left) together with a representative CAT assay and a quantitation to the right. 0 , Gal-RBoff is a potent transactivator protein and 
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Fig. 4. The ElA N-terminus and CRl are independently able to mediate p300 stimulation of transcription. Gal-R12SE/P- (ElA aa 28-142), 
Gal-R12SE/P-ACR1 (deleting aa 38-65) and Gal-MetBoiTACRl (ElA aa 1-90 with a deletion of aa 38-65) were transfected with the G5E1B-
CAT reporter plasmid in the absence or presence of p300 plasmid. Shown is the E1A-243R protein (top), the Gal4 fusion proteins (left) and a 
CAT assay with a quantitation to the right. Note that the quantitative result is given as fold stimulation caused by p300 co-transfection and 
not the relative activity of each mutant protein. 
and CRl independently of each other are able to mediate 
p300 stimulation. 
with the CRl transactivation function since both stimulate 
Gal-RBoff sub66-68 (Fig. 5B). 
3.3. CBP and p300 stimulation of transcription differ in their 
ElA sequence requirement 
Both p300 and CBP co-transfection stimulated Gal-MetB-
off (ElA aa 1-90) transactivation (Fig. 5B). Removing the N-
terminus as in Gal-RBoff or mutating aa 66-68 (Gal-RBoff 
sub66-68) did not distinguish between p300 and CBP en-
hancement of transcription. For both p300 and CBP, CRl 
is thus sufficient for stimulation and the stimulation does 
not require a functional CRl activation domain (Fig. 5A). 
Interestingly, Gal-MetBoffACRl which was efficiently stimu-
lated by p300 expression (Figs. 4 and 5B) was not stimulated 
by CBP (Fig. 5B). Thus, the ElA N-terminus or CRl inde-
pendently of each other mediate p300 stimulation. In contrast, 
CBP stimulation requires the CRl domain. Most importantly, 
neither CBP nor p300 enhancement of transcription correlates 
3.4. In vitro binding of p300 or CBP to ElA does not correlate 
with the CRl transactivation function 
To obtain additional proof that p300 or CBP interaction 
with ElA does not correlate with the activity of the CRl 
transactivator we performed in vitro protein-protein interac-
tion studies. For these experiments in vitro translated p300 
and CBP proteins were tested for their binding capacity to 
GST-E1A fusion proteins expressed in E. coli (Fig. 6). Nota-
bly, in vitro translation of both p300 and CBP yielded multi-
ple truncated protein products. This difficulty in translating 
full length p300 and CBP proteins have previously been noted 
by others [22]. In vitro translated CBP did not interact with 
GST but efficiently bound to GST-MetBoff and somewhat less 
efficiently to GST-MetBoffACRl. CBP failed to interact with 
GST-RBoff and GST-RBoff sub66-68. The binding data of 
3 
Cil-MrtBoff [ 5 5 H Z Z 1 B D * G 
Gil-KBoH fCaTl D H D " • • 0 
Cjl-RBoHsub«6-68 I Gal I G H D * f 
ClI-MrtBoffACRl | Gal I I B • % 
REPORTER 
G5E1BCAT CAT | 
B 
fold stimulation 
40 
S3 + pM0 
■ + CBP 
I I I II 
/ 
/ 
* t / / 
Fig. 5. Both p300 and CBP enhance CRl transactivation but only p300 stimulates the ElA N-terminus. (A) Representation of the E1A-243R 
protein (top) and the Gal4 fusion proteins (left). A CAT assay comparing the activating properties of Gal-MetBoff mutants in the absence of 
p300/CBP expression is shown to the right. (B) Quantitation of the stimulatory effects of p300 or CBP co-transfection. Note that the quantita-
tive result is given as fold stimulation caused by p300 or CBP co-transfection and not the relative activity of each mutant protein. 
M. Mannervik, G. Akusjcirvi/FEBS Letters 414 (1997) 111-116 
CBP 
115 
p300 
$ 4 $ $ 
?£ £ £££ 
1 m 
M . / / / / £ £ £ £ £ M 
200 
47 
4*. 
Fig. 6. Binding of CBP or p300 to ElA in vitro does not correlate with the transcription stimulatory effect. In vitro translated CBP or p300 
was tested for binding to bacterially produced GST-EIA fusion proteins. Input represents 25% of the material used in the binding reactions. 
M indicates a protein size marker. 
CBP to the MetBoff mutant proteins therefore are completely 
opposite to its effect on transcription. Thus, MetBoffACRl is 
not stimulated by CBP in co-transfection experiments but 
binds CBP, while RBoff and RBoff sub66-68 are stimulated 
by CBP but do not bind CBP. 
In vitro translated p300 efficiently bound GST-MetBoff but 
failed to interact with GST. Binding to GST-MetBoffACRl 
was somewhat reduced while binding to GST-RBoff was se-
verely reduced and no interaction with GST-RBoff sub66-68 
could be detected. Although p300 is able to efficiently stimu-
late transcription by all of these proteins, it only weakly in-
teracts with RBoif and fails to interact with RBoff sub66-68. 
In conclusion, these in vitro binding studies corroborate our 
conclusion that p300 and CBP stimulation of CR1 transacti-
vation does not require a direct interaction with ElA. These 
data are consistent with our observation that the p300del30 
protein that lacks the ElA interaction domain still stimulates 
Gal-CRl transactivation. 
4. Discussion 
We have previously shown that fusing the first 90 aa of 
ElA to the Gal4 DNA-binding domain creates a very potent 
transcription activator protein, Gal-MetBoff [5]. This region 
of ElA interacts in the context of the wt protein with the 
transcriptional co-activator proteins p300 and CBP [1]. Based 
on functional and structural similarities between the E2F1 
activation domain and the amino-terminal fragment of ElA 
(aa 1-90) it was recently proposed that ElA binding to CBP 
correlates with the CR1 activation function [23]. To test the 
hypothesis that CR1 functions as an activator by recruiting 
p300/CBP to the promoter we analyzed a number of mutants 
of Gal-MetBoff (aa 1-90) for their ability to be stimulated by 
p300 or CBP. In conclusion, our results show that ElA bind-
ing to p300 or CBP does not correlate with the CR1 activator 
function. Both p300 and CBP overexpression enhances tran-
scription by Gal-CRl. However this enhancement of Gal-CRl 
transcription appears to be independent of a direct interaction 
of p300/CBP with ElA. We show that some mutations that 
reduce or eliminate Gal-CRl transactivation can be stimu-
lated by p300/CBP co-transfection (Figs. 2 and 5). Thus, 
p300/CBP enhancement of transcription does not correlate 
with the CR1 transactivation function. Furthermore, the 
ElA N-terminus and the C-terminal part of CR1, including 
aa 66-68, which are important for the stable binding of p300/ 
CBP to the ElA wt protein ([3,24] and data not shown), are 
not necessary for p300/CBP to enhance Gal-CRl transcrip-
tion. Also, a p300 mutant protein (p300del30) that does not 
bind ElA [9] stimulates Gal-MetBoff to a similar extent as the 
wt p300 protein (Fig. 3). Similar results were obtained for all 
Gal-CRl mutants tested, including the ones unable to activate 
transcription. 
Further evidence for p300 stimulation of Gal-CRl tran-
scription-independent of a direct ElA interaction was ob-
tained by analyzing the in vitro binding characteristics of 
p300/CBP to GST-EIA fusion proteins. Most importantly, 
we observe that Gal-RBoff sub66-68 which has lost almost 
all of its activation capacity (Fig. 5), and fails to bind CBP or 
p300 in vitro (Fig. 6) was stimulated by both p300 and CBP 
co-transfection to the same extent as Gal-MetBoff (Fig. 5) 
which efficiently binds both p300 and CBP (Fig. 6). Thus, 
ElA binding to p300/CBP does not correlate with the CR1 
trans activator function. Consistent with these results, we have 
previously failed to detect an interaction of Gal-El A fusion 
proteins with p300/CBP in vivo [5]. Collectively, our results 
suggest that p300/CBP enhances transcription by ElA CR1 
independent of a direct protein-protein interaction. 
Interestingly, we found that the ElA sequence requirements 
for p300 and CBP stimulation differ. Two independent do-
mains of ElA mediate p300 stimulation; the N-terminus (aa 
1-27) and CR1 (aa 28-68) whereas CBP activation is more 
restricted requiring the E1A-CR1 domain. Thus, although 
p300 and CBP are highly related at the sequence level, their 
activities can be distinguished. Consistent with this notion, 
mutation of CBP has been implicated in the Rubinstein-Taybi 
syndrome [25], suggesting that p300 cannot compensate for 
CBP function in this disorder. 
Although the p300/CBP stimulation of Gal-MetBoff tran-
scription occurs independently of a direct interaction with 
ElA, the effect is not non-specific since Gal-CR3 transactiva-
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tion is unaffected (Fig. 1). Thus p300/CBP overexpression is 
not causing a general activation of transcription by altering 
the chromatin structure by, for example, histone acetylation 
[15]. More likely, the E l A N-terminus and the C R l domain 
interact with, at the present time, unknown cellular proteins 
that in turn recruit p300/CBP to the promoter with E1A. In 
this scenario, C R 3 or its interacting proteins would not need 
p300/CBP recruitment for function. However, the physiolog-
ical significance of such an indirect recruitment of p300/CBP 
to the E l A N-terminal fragment is questionable since Gal-
MetBoffACRl and Gal-RBoff sub66-68 by themselves do 
not function as activators (Fig. 5A). 
So far it is not clear if the C R l activator is required for lytic 
virus growth. It has been noted that activation of the adeno-
virus early promoters in primary cells require both the C R l 
and C R 3 domains [3,4]. The significance of the C R l activator 
during virus-infection of primary cells has not been directly 
tested. However, available mutat ional studies do not suggest a 
direct link between the C R l activator and E l A transactiva-
tion in non-transformed cells [3,4]. 
E l A binding of p300/CBP correlates with the ability of E l A 
to repress enhancer-dependent transcription (reviewed in [1]). 
The results presented here show that the classical E l A tran-
scription repression function and the C R l activation function 
are distinct biological activities. However, it should be noted 
that C R l represses a skeletal-muscle-specific enhancer inde-
pendently of Retinoblastoma protein or p300/CBP binding 
[26]. Thus, C R l interacting proteins other than p300/CBP 
and the Retinoblastoma family of proteins contribute to the 
multiple functions of C R l . 
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